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tolerance test showed that the antidiabetic effect of i.c.v. FGF19 was solely due to increased GE and not
to changes of either insulin secretion or insulin sensitivity. The mechanism underlying this effect appears
to involve increased metabolism of glucose to lactate. Together, these findings implicate the brain in the
antidiabetic action of systemic FGF19 and establish the brain’s capacity to rapidly, potently, and
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Insulin-independent glucose disposal (referred to as glucose effectiveness [GE]) is crucial for glucose homeostasis and, until recently, was thought to be invariable. However, GE is reduced in type 2 diabetes and markedly decreased in leptin-deficient ob/ob mice. Strategies aimed at increasing GE should therefore be capable
of improving glucose tolerance in these animals. The gut-derived hormone FGF19 has previously been shown
to exert potent antidiabetic effects in ob/ob mice. In ob/ob mice, we found that systemic FGF19 administration
improved glucose tolerance through its action in the brain and that a single, low-dose i.c.v. injection of FGF19
dramatically improved glucose intolerance within 2 hours. Minimal model analysis of glucose and insulin
data obtained during a frequently sampled i.v. glucose tolerance test showed that the antidiabetic effect of
i.c.v. FGF19 was solely due to increased GE and not to changes of either insulin secretion or insulin sensitivity.
The mechanism underlying this effect appears to involve increased metabolism of glucose to lactate. Together,
these findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the brain’s capacity to rapidly, potently, and selectively increase insulin-independent glucose disposal.
Introduction
In addition to insulin secretion and insulin sensitivity (Si), insulin-independent mechanisms are critical to normal glucose
homeostasis (1). Given that such mechanisms contribute at least
as much to normal glucose tolerance as does insulin itself (1), it is
surprising how little is known about them. This lack of research
interest can be traced to the widespread perception of insulin-independent glucose disposal, which has been termed glucose
effectiveness (GE; the ability of glucose to promote its own disposal, independently of insulin), as the fixed, obligate, and unregulated mechanism whereby insulin-insensitive tissues meet ongoing fuel needs. Yet glucose intolerance and type 2 diabetes (T2D)
are characterized by decreases of GE as well as of insulin secretion
and action (1). In leptin-deficient ob/ob mice, for example, GE was
shown recently to be reduced by approximately 70%, based on minimal model analysis of data obtained from a frequently sampled
i.v. glucose tolerance test (FSIGT) (2). Based on its importance to
glucose homeostasis, we hypothesized that any intervention capable of normalizing glucose tolerance in these mice should do so, at
least in part, by increasing GE.
FGF19 and its rodent homolog, FGF15, is one of three members of the family of hormonal FGFs. FGF19 is secreted by
enterocytes located in the distal small intestine following activation of the nuclear bile acid receptor, FXR, by bile acid binding (3). In addition to its well-established role in the negative
feedback control of hepatic bile acid synthesis (4, 5), FGF19
exerts potent antidiabetic effects in rodent models, including
ob/ob mice (6). Similarly, transgenic overexpression of FGF19
improves glucose tolerance in diet-induced obese mice (6, 7),
whereas FGF15-deficient mice display impaired glucose tolerance that is corrected by FGF19 administration (8).
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2013;123(11):4799–4808. doi:10.1172/JCI70710.

Although initially thought to act primarily via FGFR4 receptors
in the liver, the antidiabetic effects of FGF19 appear to involve
a different FGF receptor subtype, because they are preserved in
FGFR4-deficient mice (9). Instead, several findings implicate
FGFR1 in this effect. First, systemic administration of a FGF19
variant that activates FGFR1 but not FGFR4 ameliorates diabetes in ob/ob mice, while this effect is absent for a FGF19 variant
that activates FGFR4 but not FGFR1 (10). Second, the potent glucose-lowering effect of FGF19 is mimicked by monoclonal antibodies that selectively activate a specific FGFR1 isoform (FGFR1c)
(11). Although activation of FGFR1 in peripheral tissues, such as
brown and white adipose tissue, may contribute to glucose lowering, this receptor is also expressed in mediobasal hypothalamic
areas involved in glucose homeostasis (12, 13), and administration of FGF19 directly into the brain improves glucose tolerance
in both ob/ob mice (6) and diet-induced obese rats (14).
The current studies were undertaken to determine whether the
antidiabetic effect of systemically administered FGF19 involves a
central site of action and, if so, to determine the contribution(s)
made by insulin-dependent and -independent mechanisms to this
effect. We report that, in ob/ob mice, the glucose-lowering effect of
systemic FGF19 is reduced by approximately 50% when its action
in the brain is blocked by i.c.v. administration of an FGFR antagonist. Thus, the brain plays a key role in the antidiabetic effects of
this hormone. To investigate how FGF19 action in the brain affects
systemic glucose metabolism, we performed a FSIGT 2 hours after
i.c.v. injection of either FGF19 or its vehicle in ob/ob mice as well
as in vehicle-injected C57BL/6 controls. Glucose and insulin data
from the FSIGT were analyzed using the minimal model method,
which has been widely used in humans (1) and was recently validated in mice (including in ob/ob mice) (2), as a tool with which
to measure insulin secretion, Si, and GE. Surprisingly, we found
that the potent antidiabetic effect of i.c.v. FGF19 in ob/ob mice did
not involve increases of either insulin secretion or Si. Instead, the
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Figure 1
Effect on glucose tolerance of a single injection FGF19
given either centrally or systemically to ob/ob mice.
(A and C) Glucose tolerance (0.5 g/kg) and (B and D)
the integrated area under the glucose curve (AUCglucose)
in leptin-deficient ob/ob animals that received either
a single, acute i.c.v. or i.p. injection of FGF19 at either
1 or 3 μg or its vehicle. Data represent mean ± SEM.
*P < 0.05 vs. i.c.v. vehicle. #P < 0.05 vs. i.c.v. FGF19 (1 μg).

effect was mediated entirely by a 3-fold increase of GE. Furthermore, our data suggest that reduced GE in ob/ob mice is linked
to reduced glycolysis of glucose to lactate and that FGF19 action
in the CNS of these animals reverses this defect. Thus, whereas
insulin-independent glucose lowering has heretofore been considered invariant, obligate, and unregulated, our findings reveal
the brain’s inherent capacity to rapidly, potently, and selectively
increase glucose disposal via this mechanism.
Results
Effect of i.c.v. FGF19 on glucose tolerance in ob/ob mice. Since i.c.v.
FGF19 can reduce food intake and body weight as well as blood
glucose levels (6, 14), we initially sought to identify a protocol
in which effects on glucose metabolism are not confounded by
changes of energy balance. After verifying an earlier report (6)
showing that chronic (i.e., over 6 days) i.c.v. administration of
FGF19 exerts potent glucose lowering in ob/ob mice (data not
shown), we asked whether this effect can be detected following just
a single i.c.v. injection of FGF19, with food removed during the
interval (1.5 hours) between i.c.v. injection and glucose tolerance
testing. We found that, in ob/ob mice (mean body weight: 49.8 ±
1.2 g), i.c.v. injection of FGF19 lowered fasting blood glucose levels
(P < 0.05) and dose-dependently improved glucose tolerance relative to that of vehicle-treated controls (P < 0.05) (Figure 1, A and B).
Since the mice did not have access to food following i.c.v. injection, the observed effects were not due to changes of food intake or
body composition, nor were they due to leakage of FGF19 into the
periphery, since systemic administration at the same low dose had
no effect on these parameters (Figure 1, C and D). Thus, FGF19
action in the brain induces glucose lowering via a mechanism that
is unrelated to changes of energy balance.
Role of the brain in the response to systemic FGF19. Most studies of
the antidiabetic effect of FGF19 have focused on effects in peripheral tissues. To determine whether the brain also plays a role, we
asked whether the response to systemic FGF19 is attenuated by
central administration of an FGF receptor inhibitor (PD173074).
4800

Prior to undertaking this study, we verified that, when given i.c.v.,
the inhibitor blocks the response to i.c.v. FGF19. Consistent with
our earlier observations, a single i.c.v. injection of FGF19 lowered
fasting blood glucose levels and significantly improved i.p. glucose
tolerance in ob/ob mice that received an i.c.v. vehicle pretreatment
injection, and, as expected, this beneficial effect was fully blocked
by i.c.v. pretreatment with PD173074 at a dose that had no effect
when given alone (Figure 2, A and B).
We next asked whether i.c.v. pretreatment with the FGFR inhibitor affects glucose lowering induced by systemic administration
of FGF19 at a dose far higher than what is needed when given i.c.v.
(1 mg/kg vs. 3 μg). As expected, systemic administration of FGF19
lowered fasting blood glucose levels and improved glucose tolerance in ob/ob mice relative to that of vehicle-treated controls. Since
this effect was attenuated by approximately 50% by i.c.v. pretreatment with PD173074 (Figure 2, C and D), the glucose-lowering
effect of systemic FGF19 appears to be mediated at least in part
via a central mechanism.
Effect of i.c.v. FGF19 on determinants of i.v. glucose tolerance in ob/ob
mice. Having established a role for the brain in the antidiabetic
effect of FGF19, we next sought to investigate underlying mechanisms. To this end, we used the FSIGT protocol that, having been
used in human studies for many years (1), was recently validated for
use in mice, including ob/ob mice (2). Analysis of glucose and insulin data from the FSIGT using the minimal model provides quantitative estimates of insulin secretion, GE, Si, and the disposition
index (a measure of the ability of β cells to compensate for insulin
resistance). Three groups of mice were studied: ob/ob mice treated
with a single i.c.v. injection FGF19 (3 μg) or its vehicle (mean body
weight: 44.2 ± 0.8 g) and WT C57BL/6 control mice that received
i.c.v. vehicle (weight: 25.1 ± 0.5 g). This approach allowed us to
determine (a) whether the glucoregulatory effects of central FGF19
in ob/ob mice are due to increases of insulin secretion, insulin
action, or insulin-independent glucose disposal and (b) the extent
to which glucose tolerance of ob/ob mice was normalized following a single i.c.v. injection of FGF19. While fasting blood glucose
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Figure 2
Effect of a centrally administered FGF receptor blocker
on the glucose-lowering effect of FGF19. (A and C) Glucose tolerance (0.5 g/kg) and (B and D) the change in the
integrated area under the glucose curve in leptin-deficient
ob/ob mice that received either an i.c.v. pretreatment injection of the FGFR inhibitor, PD173074 (25 μg), or its vehicle
(veh) 1-hour prior to either systemic or central administration
of FGF19 or its vehicle. Animals were then subject to an ipgtt
(0.5 g/kg) 90 minutes later. Data represent mean ± SEM.
*P < 0.05 vs. i.c.v. vehicle–i.c.v./i.p. vehicle.

levels were similar in i.c.v. vehicle-treated ob/ob and WT mice,
basal plasma insulin levels were markedly elevated in the former
group, consistent with previous evidence of severe insulin resistance in these animals (2). Similarly, glucose tolerance was markedly impaired in i.c.v. vehicle-treated ob/ob mice relative to that in
WT controls following an i.v. glucose bolus (Figure 3, A and B),
despite a markedly increased acute insulin response to glucose
(a measure of first-phase insulin secretion) and sustained elevation
of plasma insulin levels throughout the study (Figure 3, C and D).
As expected, this marked impairment of glucose tolerance was
significantly improved in ob/ob mice that received FGF19 (P < 0.05)
(Figure 3, A and B). Based on the area under the glucose curve, i.c.v.
FGF19 treatment corrected the abnormality of glucose tolerance of
ob/ob mice by 65% (P < 0.05). Therefore, within 2 hours of a single
i.c.v. injection FGF19 dramatically improved glucose tolerance in
ob/ob mice. As this improvement occurred despite no difference in
plasma insulin levels at any time during the glucose tolerance test
(Figure 3, C and D), it cannot be attributed to increased insulin
secretion. We therefore turned our attention to its effects on the
two other determinants of glucose tolerance, Si and insulin-independent glucose disposal. As expected (2), minimal model analysis
of glucose and insulin data from the FSIGT revealed the Si index to
be markedly reduced in i.c.v. vehicle-treated ob/ob mice relative to
that in WT controls (Figure 3E). Unexpectedly, however, i.c.v. FGF19
injection had no effect on Si in ob/ob mice. Thus, the observed
improvement of glucose tolerance mediated by i.c.v. FGF19 was not
due to increased Si (Figure 3E), and since insulin secretion was similarly unaffected, the improvement was also not associated with an
increase of the disposition index (data not shown).
As previously reported (2), GE (defined as the ability of an
increased concentration of glucose to promote its own disposal
at basal insulin) was reduced by approximately 80% in i.c.v. vehicle-treated ob/ob mice relative to that in WT mice (Figure 3F).
Given the importance of GE as a determinant of glucose tolerance
(1), this decrease undoubtedly plays a major role in the impaired
glucose homeostasis of ob/ob mice. This assertion in turn predicts

that an increase of GE has the potential to explain the beneficial
effect of central FGF19. Consistent with this prediction, we found
that i.c.v. FGF19 induced a 3-fold increase of GE, such that it was
almost completely normalized (Figure 3F). Thus, the effect of i.c.v.
FGF19 to improve glucose tolerance in ob/ob mice results primarily from a marked increase of GE. Under the influence of FGF19,
therefore, the brain has the capacity to rapidly, potently, and selectively increase insulin-independent glucose disposal.
As a first step to better understand how the CNS action of FGF19
action increases GE, we measured plasma lactate levels during the
FSIGT, as described in Figure 3. Previous work has shown that,
in response to a glucose challenge, plasma lactate levels increase
as a consequence of glucose uptake into tissues (primarily liver),
followed by glycolysis to lactate that is subsequently released into
the circulation. Since both GE and the plasma lactate response to
glucose are reduced in obese individuals (15–17), we considered
the possibility that, in ob/ob mice, reduced GE is causally linked
to decreased metabolism of injected glucose to lactate. Consistent
with this hypothesis, we found that, as in normal humans and dogs
(17), the plasma lactate level increased rapidly but transiently following an i.v. glucose challenge in WT mice (Figure 4, A and B) and
that this effect was blunted in vehicle-treated ob/ob mice (Figure 4,
A and B). Indeed, lactate levels did not increase at all in these animals, whereas in ob/ob mice receiving i.c.v. FGF19, the plasma lactate response to i.v. glucose increased markedly (Figure 4, A and B),
as did GE (Figure 3).
To determine whether the effect of FGF19 to increase GE
involves reductions of either plasma glucagon or nonesterified
fatty acid (FFA) levels, we perf utes: 340 ± 51 mg/dl for vehicle vs.
241 ± 34 mg/dl for FGF19; P < 0.05). However, the glucose-lowering effect of FGF19 was not associated with significant changes in
the plasma level of either glucagon or FFAs (Figure 4, C and D).
Liver parameters. As a first step to investigate whether changes
of liver glucose metabolism contributed to the glucose-lowering
effect of i.c.v. FGF19, we measured baseline liver glycogen and triglyceride content as well as hepatic expression of gluconeogenic
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Figure 3
Effect of FGF19 on determinants of glucose tolerance
in ob/ob mice. (A) Blood glucose, (B) the integrated
area under the glucose curve, (C) plasma insulin levels, (D) the acute insulin response to glucose (AIRg),
(E) Si, and (F) GE in ob/ob mice or littermate controls
that received either i.c.v. vehicle or FGF19 (3 μg) and
were subjected to a frequently sampled glucose tolerance test. Data represent mean ± SEM. *P < 0.05
vs. WT i.c.v. vehicle; #P < 0.05 vs. ob/ob i.c.v. vehicle.

genes in the absence of a glucose challenge. Our data show that
while hepatic levels of G6Pase were significantly reduced in ob/ob
mice treated with i.c.v. FGF19 relative to vehicle-treated ob/ob and
WT controls, there were no differences in hepatic Pepck mRNA
levels or in either liver glycogen or triglyceride content (Figure 5).
To determine whether the effect of i.c.v. FGF19 to enhance disposal of a glucose load is associated with increased liver glycogen
content, as expected if the mechanism involves increased liver glucose uptake and glycogen synthesis, we measured liver glycogen
content 30 minutes after an i.p. glucose bolus (0.5 g/kg) in ob/ob
mice that had received i.c.v. injection of either vehicle or FGF19
(3 μg) 2 hours earlier. Consistent with our previous observations,
central FGF19 administration reduced blood glucose levels relative
to those of vehicle-treated controls both at baseline and 30 minutes after the glucose bolus (baseline: 179 ± 31 mg/dl for vehicle
vs. 106 ± 26 mg/dl for FGF19; P < 0.05; 30 minutes: 330 ± 46 mg/dl
for vehicle vs. 243 ± 5 mg/dl for FGF19; P < 0.05). However, the
glucose-lowering effect of FGF19 was not associated with a significant increase in hepatic glycogen levels (8.83 ± 0.57 mg/g tissue
for vehicle vs. 8.60 ± 1.17 mg/g tissue for FGF19; P = NS). We next
examined whether hepatic glycogen levels are increased following
an i.p. glucose bolus in ob/ob animals that receive systemic (rather
than central) FGF19 (1 mg/kg i.p.). Again, the glucose-lowering
effect of FGF19 was not associated with a significant change of
4802

hepatic glycogen levels (9.66 ± 0.93 mg/g tissue for vehicle vs. 9.37
± 0.37 mg/g tissue for FGF19; P = NS). These results indicate that,
in ob/ob mice, the effect of FGF19 to improve glucose tolerance,
selectively increase GE, and raise plasma lactate levels occurs
despite no change in liver glycogen content.
Role of melanocortin signaling in glucoregulatory effects of i.c.v. FGF19.
As the melanocortin pathway is implicated in central regulation
of glucose metabolism by leptin (18, 19), insulin (20, 21), and glucose, we asked whether (a) FGF19 activates proopiomelanocortin
(POMC) neurons in the arcuate nucleus (as judged by induction
of c-Fos staining) and (b) whether intact melanocortin signaling
is required for the glucose-lowering effect of i.c.v. FGF19. To facilitate detection of c-Fos immunoreactivity in POMC neurons, we
studied the effect of i.c.v. FGF19 in C57BL/6 mice in which POMC
cells are fluorescently labeled (Pomc-Tau-GFP mice). As depicted
in Figure 6, there was no effect of i.c.v. FGF19 to induce c-Fos in
labeled POMC cells relative to i.c.v. vehicle-treated controls.
To determine whether melanocortin signaling is required
for the glucose-lowering effects of central FGF19, we asked
whether it lowers fasting blood glucose levels or improves
glucose tolerance in melanocortin-4 receptor–deficient
(Mc4r-deficient) mice. Indeed, i.c.v. FGF19 clearly exerts a glucose-lowering action in these animals relative to that in i.c.v.
vehicle-treated animals (P < 0.05) (Figure 6, C and D). Therefore,
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Figure 4
Effect of FGF19 on plasma glucagon, FFA, and lactate levels in ob/ob mice. (A) Plasma lactate levels and
(B) the integrated area under the lactate curve (AUClactate)
during the first 20 minutes of the same FSIGT performed
in WT and ob/ob mice that received either i.c.v. vehicle
or FGF19 shown in Figure 3. (C) Plasma glucagon and
(D) FFA levels in ob/ob mice treated with FGF19
(1 mg/kg i.p.) or its vehicle, followed 90 minutes later by
an i.p. glucose bolus. Glucagon and FFA levels were measured in plasma obtained 30 minutes after the glucose
bolus. Data represent mean ± SEM. *P < 0.05 vs. WT i.c.v.
vehicle; #P < 0.05 vs. ob/ob i.c.v. vehicle.

FGF19-induced glucose lowering is mediated at least in part via
a melanocortin-independent mechanism.
Discussion
Observations made in a rat model of uncontrolled, insulindeficient diabetes suggest that the brain has the capacity to lower
blood glucose levels via insulin-independent means. Specifically,
continuous or repeated daily i.c.v. leptin administration can
normalize elevated blood glucose levels in these animals despite
persistent, severe insulin deficiency (22–25). Building upon this
initial finding, we hypothesized that, since the insulin-independent component of glucose tolerance, GE, is markedly reduced in
ob/ob mice, this defect will be remedied by FGF19 (2), because it has
potent antidiabetic effects in these animals. We further hypothesized that since FGF19 is effective following either peripheral or
low-dose central administration in these animals (6), its effect to
increase GE is mediated centrally. Our finding that glucose lowering induced by systemic FGF19 administration in ob/ob mice is
attenuated by central administration of an inhibitor of FGF receptors implicates the brain in this effect. Moreover, centrally administered FGF19 improves glucose tolerance in these animals via a
mechanism that cannot be explained by changes of insulin secretion or insulin action but arises instead from a 3-fold increase of
GE. Although a detailed understanding of mechanisms mediating
this effect awaits further study, our data support a model in which
central FGF19 increases GE by stimulating glycolysis of glucose
to lactate and in which the neuronal systems involved are at least
partially independent of melanocortin signaling. Taken together,
these data implicate the CNS in the glucose-lowering effect of
FGF19 and, to our knowledge, are the first to establish the ability
of the brain to improve glucose tolerance by rapidly, potently, and
selectively increasing insulin-independent glucose disposal. These
findings therefore establish the existence of a novel brain mechanism for insulin-independent control of blood glucose levels.
Growing evidence suggests that the CNS plays a key role in the
regulation of glucose homeostasis. In obese rodents, increased
hypothalamic input from hormonal (i.e., insulin and leptin)

or nutrient-related (i.e., FFA) signals improves hepatic Si via a
mechanism involving vagal input to the liver, whereas disruption
of this hypothalamic input causes insulin resistance (26–30). In
addition to these effects, the recent finding that continuous i.c.v.
infusion of leptin completely normalizes glycemia in rats with
streptozotocin-induced diabetes (22–25) suggests that the brain
has the capacity to potently lower glucose levels via mechanisms
that are insulin independent. To investigate the hypothesis that
FGF19 has the capacity to lower blood glucose by mechanisms
that are insulin independent, we used minimal model analysis of
glucose and insulin data from a FSIGT, an approach developed
in humans and recently validated for use in mice (2). We found
that, in ob/ob mice, a single i.c.v. injection of a low dose of FGF19
improved glucose tolerance markedly, despite having no effect
on either insulin secretion or action. The dramatic effect of centrally administered FGF19 to increase GE is remarkable, in that
with the exception of vigorous exercise (31), there is no precedent
for rapid upregulation of insulin-independent glucose disposal,
much less by the brain.
The brain’s inherent capacity to promote glucose lowering
through insulin-independent mechanisms is novel in the sense
that previous work in this area has focused largely on hypothalamic
control of hepatic Si (32, 33). That insulin-independent effects were
not identified in such studies could reflect the fact that the methods used are not optimized to detect them. The euglycemic, hyperinsulinemic clamp method, widely accepted as the “gold standard”
for quantitative assessment of glucose metabolism and Si, has been
used extensively in human as well as rodent studies. By comparison,
although minimal model analysis of FSIGT data has seen wide usage
in human research, it was only validated for use in mice in the last
year (2). This method measures not only Si and GE, but also firstphase insulin secretion and the disposition index (the product of Si
and insulin secretion, a validated predictor of progression to T2D
in humans). By comparison, the clamp (but not the minimal model
analysis) quantifies rates of glucose production and utilization and,
with some modification, can assess rates of glycogenolysis, gluconeogenesis, and glucose uptake into specific (nonhepatic) tissues.
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Figure 5
Hepatic effects of i.c.v. FGF19 in ob/ob mice. Hepatic
expression of (A) G6Pase and (B) Pepck using real-time
PCR and (C) liver triglyceride and (D) liver glycogen content in leptin-deficient ob/ob animals that received daily
i.c.v. injections of either FGF19 (3 μg) or its vehicle. Data
represent mean ± SEM. *P < 0.05 vs. i.c.v. vehicle.

Si is defined in clamp studies as the increase of glucose disposal (or decrease of glucose appearance) observed when insulin
levels are raised while glucose levels are held constant. Stated
differently, changes in rates of glucose production or disposal
measured in the face of high insulin are attributed solely to the
action of insulin. However, in the event that insulin-independent glucose disposal (or insulin-independent suppression of
hepatic glucose production) is also increased by the intervention under study, the extent to which observed changes are
attributable to insulin action cannot be known with certainty,
since some of the glucose infused during the clamp (to maintain
euglycemia in the presence of high insulin) would have been disposed of via insulin-independent mechanisms. Thus, whether
insulin-independent mechanisms contributed to some of the
centrally mediated effects attributed previously to changes of Si
(32, 33) awaits additional study.
The insulin-independent component of glucose disposal in
sedentary subjects has historically been considered to be a fixed,
obligate, and invariant means whereby insulin-independent tissues
obtain glucose primarily via the process of glucose mass action, by
which increasing concentrations of glucose passively drive glucose
into cells in a largely unregulated manner (1). It is for this reason
that research into mechanisms underlying insulin-independent
glucose disposal has languished in comparison with the substantial
effort and progress made toward understanding insulin secretion
and its action in peripheral tissues. Nevertheless, data from clinical studies performed years ago offer evidence suggestive of regulation. For one, i.v. infusion of glucagon-like peptide-1 (GLP-1)
in humans improves i.v. glucose tolerance by increasing GE as
well as insulin secretion (34), while, conversely, GE was reduced
following i.v. administration of a somatostatin analog, an effect
that impairs glucose tolerance beyond what can be explained by
the associated inhibition of insulin secretion (35). Although the
mechanism underlying these effects on GE is unknown, our data
with FGF19 raise the possibility of an action mediated in the brain.
Although our conclusions regarding the role of GE in the
antidiabetic effect of FGF19 are based primarily on studies conducted in ob/ob mice, we believe that these findings have broader
implications. First, our findings are compatible with several
4804

studies showing that, in rodent models of severe insulin-deficient diabetes, leptin administration can fully normalize blood
glucose levels, despite persistent insulin deficiency (22–25).
The effect is therefore insulin independent, and, moreover, it
is mediated centrally, since the effect is observed when leptin is
given i.c.v. at a much lower dose than is required during systemic
administration. Combined with the current studies, these observations establish brain’s inherent capacity to induce dramatic,
insulin-independent glucose lowering and provide a compelling
rationale for investigation into underlying mechanisms and their
clinical relevance. The question of whether centrally active mediators other than leptin and FGF19 can increase GE is also relevant. For example, FGF21 exerts antidiabetic effects analogous
to those induced by FGF19, and both hormones appear to signal
via the same receptor (FGFR1), but whether FGF21 increases GE
is unstudied. In addition to candidate peptides, an increase of
circulating glucose levels is itself well known to increase GE, and
the possibility that this involves an effect of glucose in the brain
is consistent with available data (36).
The contribution made by insulin-independent mechanisms to
overall glucose homeostasis is surprisingly large. Available evidence
suggests that GE accounts for approximately 50% of glucose disposal in humans following an i.v. glucose challenge (in rodents, the
contribution may be greater), with the remaining 50% attributable
to the combined effects of insulin action and insulin secretion (1).
It is noteworthy in this context that, like insulin resistance, reduced
GE makes an important contribution — perhaps comparable to
that of insulin resistance — to impaired glucose tolerance and T2D
in humans (1, 37). Consequently, reduced GE is a strong risk factor
for the development of T2D (38). Combined with our current findings, the possibility that a central defect contributes to impaired
GE in obesity-associated metabolic impairment can be considered.
Related questions of strong translational interest include whether
defects in CNS sensing or responsiveness to FGF19 or other inputs
contribute to common clinical disorders of glucose homeostasis and whether interventions that increase GE have therapeutic
potential in individuals with obesity and diabetes.
As a first step to investigate how FGF19 action in the brain
increases GE, we measured the increment of plasma lactate
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Figure 6
Central targets of FGF19 action. (A and B) Immunodetection of POMC (green) and the colocalization of c-fos in POMC neurons in Pomc-Tau-GFP
mice treated with i.c.v. administration of either (A) vehicle or (B) FGF19 (original magnification, ×20; Scale bar: 20 μm). (C) Glucose tolerance
(0.5 g/kg) and (D) the integrated area under the glucose curve in Mc4r–/–mice that received a single, acute i.c.v. injection of FGF19 (3 μg) or its
vehicle. Data represent mean ± SEM. *P < 0.05 vs. i.c.v. vehicle. 3V, third ventricle.

levels that follows a glucose challenge. The rationale for this
approach begins with evidence published some 40 years ago
that plasma lactate levels increase following consumption of a
mixed meal in humans (39). Subsequent studies showed that
this response results not from lactate absorption from the GI
tract, but from the uptake of glucose into tissues, followed by
its metabolism to lactate that is subsequently released into the
circulation (40, 41). Since the same glucose→lactate metabolic
response occurs after an i.v. glucose challenge, calories do not
need to enter the body from the GI tract to elicit this response
— an increased circulating glucose level is sufficient (15). Interestingly, the effect of either oral or i.v. glucose to increase lactate
levels is reduced in obese humans (15), as is GE (1). We therefore asked (a) whether reduced GE in ob/ob mice is associated
with blunting of the glucose→lactate response and (b) whether
FGF19 action in the brain increases GE in part by stimulating
this process. Our data are consistent with both predictions. We
found that the plasma lactate level increased rapidly following
an i.v. glucose challenge in WT mice, whereas lactate levels did
not increase at all in vehicle-treated ob/ob mice, consistent with
their markedly reduced GE (by ~70%). In contrast, both GE and
the plasma lactate response to i.v. glucose increased markedly in
ob/ob mice receiving i.c.v. FGF19. Together, these findings support a model in which (a) reduced GE in ob/ob mice results in
part from a decreased glucose→lactate metabolic response, (b)
the effect of FGF19 to increase GE involves an increase in this
response, and (c) the brain mediates this effect of FGF19.
The identification of tissues in which this glucose→lactate
response occurs in mice awaits further study. In dogs and
humans, the liver is implicated, and it is notable in this
context both that liver glucose uptake is insulin independent and that the brain plays a fundamental role to regulate this process (38). However, our finding that the effect
of FGF19 to increase GE is not associated with increased
liver glycogen content in ob/ob mice raises questions regarding whether liver glucose uptake is increased, and both fat
and skeletal muscle can also metabolize glucose to produce
lactate that is subsequently released into the circulation
(42, 43). Additional studies are therefore needed to definitively
identify the tissue(s) involved.
Although our findings support the hypothesis that the antidiabetic effects of FGF19 involve a central site of action, we empha-

size that they do not preclude a role for peripheral tissue effects
as well (8, 44). FGFR1 activation exerts glucose-lowering effects
in liver as well as both brown and white adipose tissue (11), and
the beneficial effects of systemic FGF19 on glucose tolerance that
we observed in ob/ob mice were only partially blocked by central
FGF receptor blockade. Future studies using targeted disruption
of FGF receptor signaling in a tissue-specific manner will help to
clarify the extent to which glucoregulatory effects of FGF19 are
mediated centrally versus peripherally.
In addition, little is known regarding the neurocircuitry underlying central FGF19 action, although our data implicate a mechanism independent of melanocortin signaling. This assertion is
based on our findings that FGF19 failed to induce c-Fos (a marker
of neuronal activation) in hypothalamic POMC neurons and that
FGF19 improved glucose tolerance in Mc4r-deficient mice (albeit,
not to the same extent as was observed in ob/ob mice). Whatever
the underlying neurocircuitry, convergent lines of evidence that
implicate activation of FGFR1 in the antidiabetic effects of FGF19
(and FGF21, as well) (9, 10) and the observation that FGFR1 is
expressed in key hypothalamic areas implicated in metabolic regulation (12, 13) support a model in this brain area that mediates
the increase of GE induced by FGF19. Additional studies are warranted to test this hypothesis.
Whether FGF19 plays a physiological role in glucose homeostasis or diabetes pathogenesis is still largely unstudied. Also of
interest is the as yet untested hypothesis that beneficial metabolic effects of bariatric surgical procedures are tied to increased
FGF19 secretion from gut enterocytes. Consistent with this
possibility, circulating levels of bile acids (45, 46) and FGF19
increase following roux-en-Y gastric bypass (RYGB) surgery in
humans (47, 48). As bile acid stimulation of FGF19 secretion
is mediated via FXR, these data collectively raise the possibility
that increased bile acid–induced stimulation of FGF19 secretion (and increased GE) contributes to the high rate of diabetes remission induced by RYGB (49), but a direct test of this
hypothesis is still awaited.
In conclusion, our findings suggest that the glucose-lowering
effect of systemic FGF19 involves a novel central mechanism
whereby insulin-independent glucose disposal is rapidly, potently,
and selectively increased. The finding that the brain has the inherent ability to lower blood glucose levels via such a mechanism
opens new potential avenues for diabetes drug discovery.
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Methods
Animals. All animals were housed individually under specific pathogen–free conditions in a temperature-controlled room with a 12-hour
light/12-hour dark cycle. Animals were provided with ad libitum access
to water and standard laboratory chow (PMI Nutrition International
Inc.) unless otherwise stated. Adult, male ob/ob mice on the C57/Bl6
background and their WT littermates were obtained from The Jackson
Laboratory. To better identify POMC cells, we used Pomc-Tau-eGFP
mice that were provided to us by Tomas Horvath at Yale University (New
Haven, Connecticut, USA), in which T-topaz GFP is expressed under the
transcriptional control of the POMC promoter and backcrossed onto
the C57/Bl6 background for >10 generations (50). Mc4r–/– mice, originally derived as discussed in ref. 51, were obtained from breeding colonies maintained at the University of Washington.
Surgery. Animals underwent cannulation of the lateral ventricle (Plastics One) under isoflurane anesthesia at stereotaxic coordinates based on
the brain atlas of Paxinos and Watson (52): –0.7 mm posterior to bregma;
1.3 mm lateral, and 1.3 mm below the skull surface. The cannula was
permanently fixed to the skull using glass ionomer cement (Instech Solomon) and was closed with an obturator. Animals received buprenorphine
hydrochloride (Reckett Colman Pharmaceuticals) at the completion of the
surgery and were allowed to recover for at least 5 days while food intake
and body weight were recorded. i.c.v. injections were administered using a
(33-gauge) needle that extended 1 mm beyond the tip of the cannula over a
period of 60 seconds in a final volume of up to 1.5 μl. The injector was then
allowed to remain in place for an addition 60 seconds before removal. For
studies involving a FSIGT, adult male C57/Bl6 and ob/ob mice underwent
lateral ventricular cannulation as above as well as catheterization of both
the carotid artery and jugular vein, as described in detail previously (53).
Body composition analysis. Liver triglyceride content and measures of total
fat and lean body mass were determined using quantitative magnetic
resonance spectroscopy (EchoMRI 3-in-1 Animal Tissue Composition
Analyzer; Echo Medical Systems) using the Energy Balance and Glucose
Metabolism Core of the Nutrition Obesity Research Center at the University of Washington. Liver glycogen levels were determined using a colorimetric assay (Biovision) and were standardized to grams wet weight.
i.p. glucose tolerance testing. i.p. glucose tolerance tests (ipgtt; 30% d-glucose;
0.5 or 1.5 g/kg) were conducted in 5-hour fasted animals. Blood glucose levels were measured at t = 0, 15, 30, 60, 90, and 120 minutes using
a hand-held glucometer (Accu-Chek) to test blood obtained from tail
capillary samples.
CNS FGF receptor signaling in the glucose-lowering effects of FGF19 in
ob/ob mice. To determine whether increased FGF19 signaling in the
brain is sufficient to improve glucose tolerance, adult male ob/ob mice
were matched for body weight, food intake, and blood glucose levels
and fasted at 09:00. At 11:30, animals received a single, acute i.c.v. injection of either vehicle (0.9% saline) or FGF19 (Phoenix Pharmaceuticals)
at a dose of 1 μg or 3 μg. At 13:00, animals were subjected to an ipgtt
(0.5 g/kg). Animals followed the same paradigm as described above,
except that they received an i.p. injection of FGF19 at the same doses
as administered i.c.v.
To determine whether the glucose-lowering effect of FGF19 involves
activation of FGF receptors in the CNS, a separate cohort of ob/ob mice
was matched for body weight, food intake, and blood glucose levels and
fasted at 09:00. Ninety minutes later, animals received either an i.c.v. preinjection of the FGFR inhibitor, PD173074 (Sigma-Aldrich; 25 μg), or its
vehicle (100% DMSO). Relative to vehicle-treated controls, this dose had
no effect by itself on either fasting blood glucose levels or glucose tolerance (data not shown). To confirm that the glucose-lowering effect of
i.c.v. FGF19 is receptor mediated, animals received an i.c.v. injection of
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FGF19 (3 μg) or its vehicle 1 hour after pretreatment injection. At 13:00,
animals were then subjected to an ipgtt (0.5 g/kg). Once the efficacy
of the inhibitor was validated against i.c.v. FGF19, we asked whether
pretreatment blunts the antidiabetic effect of FGF19 following systemic
administration at a higher dose. Adult male ob/ob mice followed the
same protocol as described above, except that they received a systemic
(rather than i.c.v.) injection of FGF19 (1 mg/kg).
To determine whether the glucose-lowering effects of i.c.v. FGF19 require
melanocortin signaling, adult male Mc4r–/– mice bred onto the C57BL/6
background and matched for age, body weight, and blood glucose were
subjected the above protocol, in which an ipgtt (1.5 g/kg) was performed
90 minutes following i.c.v. injection of FGF19 (3 μg) or its vehicle.
Effect of chronic i.c.v. FGF19 on blood glucose levels in ob/ob mice. To determine whether chronic i.c.v. administration of FGF19 ameliorates
diabetes in ob/ob mice, adult male ob/ob mice matched for body weight,
food intake, and blood glucose levels received daily i.c.v. injections of
FGF19 (3 μg) or its vehicle for 5 consecutive days. Body weight, food
intake, and blood glucose levels were recorded daily. At the completion
of the study, animals were perfused, and brains removed and processed
for immunohistochemical outcomes, as described below. To determine
whether the glucose-lowering effects of CNS FGF19 could be explained by
leakage into the periphery, a similar paradigm was used, except that ob/ob
mice received daily peripheral injections of FGF19 (3 μg) or its vehicle at
the same dose that was administered i.c.v.
FSIGT. A FSIGT was performed in 5-hour fasted ob/ob mice or their littermate controls at least 5 days following LV cannulation and arterial and
venous catheterization. Blood sampling was performed via the arterial
catheter in unrestrained, conscious animals. A baseline fasted blood sample
was taken at –10 and 0 minutes. Based on a previous protocol (2), a 1 g/kg
bolus of 50% dextrose was injected i.v. over a period of 15 seconds at t = 0
minutes. Blood (20 μl) was sampled for measurement of glucose and subsequent assay of plasma insulin at time points 1, 2, 4, 8, 12, 16, 20, 30, and
60 minutes. Additional samples were obtained for glucose measurement
alone at 3, 5, 6, 10, 14, 18, 25, 40, and 50 minutes. Throughout the entire
procedure, beginning at –10 minutes, mice received i.v. infusion of salinewashed erythrocytes (5 μl/min) to prevent the significant fall in hematocrit
that would otherwise occur. Blood glucose levels were measured on a handheld glucometer (Accu-Chek).
Minimal model analysis of FSIGT data. Based on glucose and insulin curves, glucose disposal was divided into 3 phases: mixing phase
(0–2 minutes), GE-dominated phase (2–5 minutes), and insulin-dominated phase (5–60 minutes) (2). The mixing phase was not used for Si
or GE modeling. Acute insulin response to glucose was based on insulin
values between 0 and 4 minutes. All Si calculations are multiplied by 104.
Data were modeled using MinMod software modified for phase durations as stated above and GE starting estimate.
Effect of i.c.v. FGF19 on c-fos induction in Pomc-Tau-eGFP mice. To determine whether FGF19 activates POMC neurons in the hypothalamus,
female Pomc-Tau-eGFP mice underwent lateral ventricular cannulation,
as described previously. Following a 1-week recovery period, habituated
animals were fasted for 3-hours and then received an i.c.v. injection of
either saline or FGF19 (3 μg). Ninety minutes later, mice were perfused,
with brains removed and processed for immunohistochemical outcomes, as described below.
Tissue collection and processing. For immunohistochemical studies, mice
were anesthetized with ketamine/xylazine and perfused with PBS followed
by 4% PFA in 0.1 M PBS. Brains were removed, post-fixed in 4% PFA overnight, embedded in 25% sucrose solution for 48 hours at 4°C, snap frozen
in isopentane, and cooled with liquid nitrogen. The hypothalamus was
sectioned at 14 µM in the coronal plane using a freezing cryotome, slide-
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mounted, and stored at –80°C until selection for immunohistochemical
staining or visualization of GFP by fluorescence microscopy.
Double-label immunofluorescence. For colocalization studies, anatomically
matched sections throughout the hypothalamus were selected for staining. Briefly, slides were washed with 10 mM PBS at room temperature
and were then blocked for 30 minutes with buffer containing 5% normal
donkey serum, 0.1% BSA, and 0.01% Triton-X in 10 mM PBS. Following
additional washes, slides were incubated overnight at 4°C in a “cocktail”
of primary antibodies, including goat polyclonal anti-GFP (Fitzgerald
Industries) diluted 1:10,000 with rabbit polyclonal anti–c-Fos (Oncogene
Research Products) diluted 1:100,000. Slides were washed with PBS and
then incubated for 120 minutes at room temperature with the secondary
antibodies (a) 1:1,000 donkey anti-goat IgG-Alexa Fluor 488 (Life Technologies) and (b) 1:1,000 donkey anti-rabbit Alexa Fluor 594 (Life Technologies), diluted in 5% normal donkey serum and 0.1% BSA in 10 mM
PBS. After washing with PBS, slides were subsequently coverslipped with
an antifade aqueous mounting media. Control sections were incubated
with normal serum and did not show staining.
Plasma analysis. Blood samples for measures of insulin, lactate, and FFAs
were collected in EDTA-treated tubes, while blood for glucagon assay was
collected on tubes containing 10 μl of 1 M benzamidine and 1 U of heparin. Blood was centrifuged and plasma was removed, aliquoted, and stored
at –80°C. Plasma immunoreactive insulin levels were determined by ELISA
(Crystal Chem), FFA levels were determined using a colorimetric assay
(Wako Chemicals), plasma lactate levels were determined using a GM9D
glucose direct analyzer (Analox Instruments), and plasma glucagon levels
were determined using a glucagon RIA kit (Linco Research).
RT-PCR. Total RNA was extracted from liver using TRIzol B according to manufacturers’ instructions (MRC). RNA was quantitated by
spectrophotometry at 260 nm (Nanodrop 1000, Thermo Scientific) and
reverse-transcribed with AMV reverse transcriptase (1 μg) (Promega). Realtime PCR was performed on a ABI Prism 7900 HT (Applied Biosystems)
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using the commercially available PCR Master Mix (SYBR Green, Applied
2.0; Applied Biosystems) and analyzed as previously described (22, 26).
Statistics. All results are expressed as mean ± SEM. Statistical analyses
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variance showed P < 0.05, and a 2-sample unpaired Student’s t test
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